Trade

Watchlist

Portfolio

Message

Set Alert

BSE LIVE NSE LIVE 26 Aug, 2025 12:21 Volume Todays L/H More ×

Dr. Reddy’s Laboratories is banking on three strategic launches—semaglutide in Canada, denosumab in the U.S. and Europe, and biosimilar abatacept (against rheumatoid arthritis) — to revive growth in its US business and counter the steep price erosion triggered by loss of limited exclusivity of generic anti-cancer drug Revlimid (lenalidomide).

“Semaglutide, denosumab and abatacept are the three molecules that will help us mitigate the impact of declining Revlimid sales and bring back growth momentum,” said M.V. Narasimham, Chief Financial Officer, in a post-earnings interview. He added that while some quarters may see pressure, the company expects single-di

See Full Page